As Seen In

As Seen In
Total Tutor with Neil Haley
8 years ago Nov 27, 2016
The Total Tutor Neil Haley will interview Lee Buckler of Replicel. Click here to view:...
As Seen In
Shiseido to trial baldness ‘cure’ for planned commercial launch in 2018
9 years ago Mar 22, 2016
Find full article here online, at The Asahi Shimbun.
As Seen In
Embrace Low-Cap Biotech for High Gains: Eden Rahim of Next Edge Capital
9 years ago Mar 02, 2016
Source: George S. Mack of The Life Sciences Report (3/2/16) View the full article as...
As Seen In
How Japan ‘Changed the System’
9 years ago Nov 15, 2015
Japan’s Bold Steps By: Iain Marlow ASUKE, JAPAN The Globe and Mail Last updated: Saturday, Nov....
As Seen In
Canada’s emerging cell therapy biotech industry
9 years ago Oct 26, 2015
Canadian companies driving global breakthroughs in regenerative medicine By Kathryn Boothby To read this article...
As Seen In
Japan’s regulatory gamble and what it means for the Industry
9 years ago Sep 15, 2015
Navigating the Global Regulatory Landscape Written by: Lee Buckler & Colin Lee Novick The Follower...
As Seen In
Alan Leong of BioWatch Looks Beyond the Buzz for Solid Early-Stage Plays RP, CAPR, CTRV, CPXX, SRNE, SNSS
9 years ago Sep 08, 2015
To read the full article as it appears on The Life Sciences Report, click here....
As Seen In
Harness Biotech Volatility with an Options Strategy: Theta Strategy Capital’s Eden Rahim
9 years ago Aug 11, 2015
To read the full article as it appears on The Life Science Report, please click...
As Seen In
Regenerative Medicine in Japan: CJ Partners’ Colin Lee Novick
9 years ago Aug 04, 2015
Source: Gail Dutton of The Life Sciences Report Regenerative medicine is just beginning to be...
As Seen In
5 Questions with David Hall
9 years ago Jul 15, 2015
Click here to view the article on Cantech LetterVancouver-based RepliCel Life Sciences (TSXV:RP) concentrated on...
As Seen In
Japan’s Gambit for Cell Therapy Clinical Trials
10 years ago May 28, 2015
Please click here to visit Fisher BioServices Blog. Posted by Richard Tsai on May 28,...
As Seen In
Stem cell ‘Wild West’ takes root amid lack of US regulation
10 years ago May 17, 2015
Business | By Matthew Perrone | AP May 18, 2015 In this Dec. 5, 2014...
As Seen In
Injured Athletes Could get Back in the Game Putting New Cells to Work on old Injuries
10 years ago May 13, 2015
Clinical trials underway for chronic Achilles tendinosis By: Tammey George Being sidelined due to an...
As Seen In
Impact Magazine: Aching Achilles?
10 years ago May 11, 2015
Regenerative Medicine Promises New Cure for Chronic Tendon InjuriesBy Dr. Jack TauntonA Regerative Cell therapy...
As Seen In
The Province: UBC achilles research could be key to revolutionary treatment
10 years ago May 10, 2015
University studying the injection of cultivated cells from one’s own body to speed the healing...
As Seen In
Stockhouse: Tech Roundup – RepliCel (V.RP) grows, SoMedia (V.VID) profits, WiLAN (WILN) flounders
10 years ago May 03, 2015
By: Gaalen Engen First here’s a little biotech. RepliCel Life Sciences (TSX: V.RP, Stock Forum)...
As Seen In
Japan’s Take on Regenerative Medicine: Early Commercialization, Early Reimbursement
10 years ago Apr 26, 2015
By Gail Dutton, Contributing Editor Follow Me On Twitter @GailLdutton New regulations accelerating the approval...
As Seen In
How to Grow a Regenerative Medicine Industry in Canada: Michael May of CCRM
10 years ago Apr 23, 2015
Source: George S. Mack of The Life Sciences Report (4/23/15)There’s a new kind of incubator...
As Seen In
Cell Therapy is “Hair Raising” in a Good Way
10 years ago Apr 14, 2015
RepliCel Targets Low-Risk, Near-Term Opportunities in Regenerative MedicineBy: Gail DuttonThe regenerative medicine company RepliCel Life...
As Seen In
The Life Sciences Report: Will Stem Cell Profits Measure Up?
10 years ago Mar 18, 2015
To read the article on The Life Sciences Report, click here: It makes no sense...

by Type

by Topic

by month

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.